Assertio Holdings (ASRT) Asset Writedowns and Impairment (2023 - 2026)
Assertio Holdings' (ASRT) quarterly Asset Writedowns and Impairment came in at $198000.0 in Q1 2026, down 63.2% year-on-year from $538000.0 in Q1 2025, and up 107.4% quarter-over-quarter from -$2.7 million in Q4 2025.
Assertio Holdings (ASRT) Asset Writedowns and Impairment (2023 - 2026) Analysis & Trends
Assertio Holdings has disclosed Asset Writedowns and Impairment across 4 years of filings, most recently posting $198000.0 for Q1 2026.
- Asset Writedowns and Impairment for Q1 2026 came in at $198000.0, down 63.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (down 83.39% YoY), and the FY2025 annual result was $1.7 million, down 67.41% from the prior year.
- Asset Writedowns and Impairment came in at $198000.0 for Q1 2026 at Assertio Holdings, up from -$2.7 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $238.8 million in Q3 2023 to a low of -$2.7 million in Q4 2025.
- The 4-year median for Asset Writedowns and Impairment is $1.9 million (2025), against an average of $25.5 million.
- Across the five-year window, Asset Writedowns and Impairment gained 8.33% in 2024 and sank 151.44% in 2025, its largest moves.
- Assertio Holdings' Asset Writedowns and Impairment stood at $4.8 million in 2023, then gained by 8.33% to $5.2 million in 2024, then slumped by 151.44% to -$2.7 million in 2025, then jumped by 107.4% to $198000.0 in 2026.
- The last three Asset Writedowns and Impairment figures came in at $198000.0 (Q1 2026), -$2.7 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 198,000.00 |
| Mar 31, 2026 | 198,000.00 |
| Dec 31, 2025 | -2.68 Mn |
| Dec 31, 2025 | -2.68 Mn |
| Sep 30, 2025 | 1.70 Mn |
| Sep 30, 2025 | 1.70 Mn |
| Jun 30, 2025 | 2.14 Mn |
| Jun 30, 2025 | 2.14 Mn |
| Mar 31, 2025 | 538,000.00 |
| Mar 31, 2025 | 538,000.00 |
| Dec 31, 2024 | 5.20 Mn |
| Dec 31, 2024 | 5.20 Mn |
| Jun 30, 2024 | 2.45 Mn |
| Jun 30, 2024 | 2.45 Mn |
| Mar 31, 2024 | 1.43 Mn |
| Mar 31, 2024 | 1.43 Mn |
| Dec 31, 2023 | 4.80 Mn |
| Dec 31, 2023 | 4.80 Mn |
| Sep 30, 2023 | 238.80 Mn |
| Sep 30, 2023 | 238.80 Mn |